PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AstraZeneca reveals new research to improve drug discovery

The study used data from 50,000 people in the UK Biobank.

AstraZeneca (AZ) researchers have revealed thousands of associations between rare genetic variants and plasma proteins, which could improve future drug discovery research and treatment approaches.

Results from the study were collated using data from over 50,000 individuals in the UK Biobank.

Published in Nature, AZ researchers analysed the effects of rare genetic variants on over 3,000 proteins in the body and identified over 4,400 significant protein quantitative trait loci, which are gene variants associated with protein function essential to health.

Proteins are the functional units of cells, which have a number of important roles throughout the body and are controlled by genes contained on chromosomes.

In comparison to common genetic variants, rare variants produce stronger evidence and unique insights into the connection between genes and proteins and their roles in disease.

More than 75% of the protein quantitative trait loci had never been detected before and provided additional insight to a companion study to analyse common variants in a similar UK Biobank group.

Medicines that target genes or proteins linked to human disease are more likely to deliver clinically meaningful outcomes.

Findings from the study will enhance the ability to understand disease and discover new targets for drug discovery.

AZ’s findings from the study are being applied to further scientific understanding of disease mechanisms, potential off-target drug effects, novel target identification and biomarker discovery to accelerate drug discovery and development (R&D) within the company’s research and development pipeline.

Slavé Petrovski, vice president, Centre for Genomics Research, Discovery Sciences, R&D, AZ, said: “To successfully treat a disease, we benefit from understanding the underlying molecular cause. This research breaks new ground by showcasing connections between genetic variants and proteins that we have never seen before.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026